NRX Pharmaceuticals, Inc.
NRX-100
ketamine
Resolved
140days ago
Advisory committee · Feb 17, 2026
What's at stake
An FDA advisory committee reviews NRX-100 for ketamine around Feb 17, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“On February 17, 2026, NRx Pharmaceuticals, Inc. (the “Company”) issued a press release regarding a path to a new drug application with real world data and broader proposed indication for NRX-100 (ketamine) Following Type C FDA Meeting.”